Publication | Open Access

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial

Hematological MalignancyLymphoid NeoplasiaChronic Lymphocytic LeukaemiaMedicineYounger PatientsImmunologyClinical TrialsHematologyImmune Checkpoint InhibitorPharmacotherapyPhase 2ImmunotherapyOncologyHealth Sciences